Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Rhea-AI Summary
Axogen (Nasdaq: AXGN) will release fourth quarter and full year 2025 financial results on February 24, 2026. Management will host an investor conference call and webcast at 8:00 a.m. ET following the release.
Investors can join by phone at the provided toll-free or direct dial numbers, and a live webcast, archived replay, and presentation slides will be available on the company Investors page at www.axogeninc.com.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
AXGN fell 2.86% while key medical device peers were mixed: SIBN (-1.09%), TNDM (-2.33%), IRMD (-0.77%), OFIX (+2.27%), AVNS (-1.45%). Moves do not show a clear, unified sector direction.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 21 | Equity offering priced | Negative | +3.6% | Priced upsized public offering of 4,000,000 shares at $31.00 per share. |
| Jan 21 | Equity offering proposed | Negative | +3.6% | Announced proposed $85.0M common stock offering with 30-day underwriter option. |
| Jan 12 | Preliminary 2025 results | Positive | -5.8% | Preliminary Q4 and full-year 2025 revenue growth above 20% with strong margins. |
| Dec 17 | Conference participation | Positive | +7.0% | Announced presentation at the J.P. Morgan 2026 Healthcare Conference for investors. |
| Dec 03 | FDA Avance approval | Positive | +2.3% | FDA approved Avance BLA for multiple peripheral nerve indications, including accelerated approval. |
Recent news often produced strong but mixed reactions, with both positive fundamentals and dilutive offerings sometimes moving opposite to intuitive expectations.
Over the past few months, Axogen reported several key developments. On December 3, 2025, the company received FDA approval for its Avance biologic, followed by participation in the J.P. Morgan 2026 Healthcare Conference. On January 12, 2026, Axogen released strong preliminary 2025 revenue of about $225.2 million with gross margin above 74%. Shortly after, the company launched and priced an upsized equity offering of 4,000,000 shares at $31.00, aimed in part at repaying its Oberland credit facility. Today’s earnings-date announcement fits into this ongoing disclosure cadence around 2025 performance.
Regulatory & Risk Context
Axogen has an effective automatic shelf registration on Form S-3ASR dated January 21, 2026, allowing it to issue common stock, preferred stock, debt securities, and warrants in one or more future offerings. The shelf has no stated aggregate limit in the filing summary, and potential proceeds are generally earmarked for corporate purposes such as working capital and capital expenditures.
Market Pulse Summary
This announcement schedules the release of Axogen’s final Q4 and full-year 2025 results for February 24, 2026, following earlier preliminary revenue of about $225.2M and gross margin above 74%. Investors already know the company executed an upsized 4,000,000-share offering at $31.00 and has an active S-3ASR shelf, alongside FDA approval for Avance. Key items to watch in the upcoming report are audited financials, margin details, cash trends, and any updates on capital allocation and post-approval commercialization plans.
AI-generated analysis. Not financial advice.
ALACHUA, Fla. and TAMPA, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the fourth quarter and full year 2025 on Tuesday, February 24, 2026. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release.
Investors interested in participating in the conference call by phone may dial toll-free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. A live webcast, an archived replay, and presentation slides from the event are available on the Investors page of the company's website at www.axogeninc.com.
About Axogen
Axogen (Nasdaq: AXGN) is focused on the science, development and commercialization of technologies for peripheral nerve repair. With a mission to make nerve repair the expected standard of care, Axogen advances the field through research, education, and collaboration with surgeons and healthcare providers across a global network.
Axogen’s product portfolio includes Avance® (acellular nerve allograft-arwx), Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™.
Contact:
Axogen, Inc.
InvestorRelations@axogeninc.com
FAQ
When will Axogen (AXGN) report Q4 and full year 2025 results?
How can investors join Axogen's (AXGN) February 24, 2026 earnings call?
Where will Axogen (AXGN) post the webcast replay and presentation slides?
What time is Axogen's (AXGN) investor call for the 2025 results?
Will Axogen (AXGN) provide an archived replay of its February 24, 2026 presentation?
